Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use. (Q33655234)

28 July 2017

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use. (English)

1 reference

28 July 2017

7

Bart Barlogie

1 reference

28 July 2017

Ryan van Laar

1

1 reference

28 July 2017

Rachel Flinchum

2

1 reference

28 July 2017

Nathan Brown

3

1 reference

28 July 2017

Joseph Ramsey

4

1 reference

28 July 2017

Sam Riccitelli

5

1 reference

28 July 2017

Christoph Heuck

6

1 reference

28 July 2017

John D Shaughnessy

8

1 reference

28 July 2017

17 May 2014

1 reference

28 July 2017

1 reference

28 July 2017

7

1 reference

28 July 2017

25

1 reference

describes a project that uses

28 July 2017

SQL

1 reference

26 June 2022

https://europepmc.org/article/PMC/PMC4032347

based on heuristic

inferred from PubMed Central ID database lookup

exact match

https://scigraph.springernature.com/pub.10.1186/1755-8794-7-25

0 references

cites work

Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Prediction of cytogenetic abnormalities with gene expression profiles

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

The molecular classification of multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Using genomics to identify high-risk myeloma after autologous stem cell transplantation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Bioconductor: open software development for computational biology and bioinformatics

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Gene expression profiling predicts clinical outcome of breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Molecular portraits of human breast tumours

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

Molecular classification of cutaneous malignant melanoma by gene expression profiling

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4032347

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1755-8794-7-25

Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1755-8794-7-25

Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1755-8794-7-25

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1755-8794-7-25

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1755-8794-7-25

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1755-8794-7-25

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24885236

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24885236

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1755-8794-7-25

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference